Sanjay Bhatia, Managing Director, Ajay Bhatia, Chairman

Parag Bhatia & Arpit Bhatia, Director

The pharmaceutical industry is a critical sector responsible for the research, development, production, and distribution of medications and healthcare products. It plays a vital role in improving public health by providing treatments for various medical conditions, preventing diseases, and enhancing overall well-being. Factors like the aging population, emerging markets, pandemic preparedness, and supportive regulations are propelling the industry's growth. However, consumers in the pharmaceutical industry face challenges such as limited access to medications in certain regions, the presence of counterfeit drugs, and health inequality due to disparities in healthcare resources. These issues underscore the importance of improving medication access, ensuring drug quality, and promoting equitable healthcare opportunities for all. Addressing these challenges, Laborate Pharmaceuticals emerges as a solution provider. A solution-oriented company dedicated to produce premium quality pharmaceuticals at affordable prices.

With a commitment to manufacturing premium quality products, the company aims to address unmet medical needs, including rare diseases. By ensuring affordability and accessibility through innovative distribution models, Laborate Pharmaceuticals seeks to improve global healthcare outcomes. With cutting-edge research and a patient-centric approach, the company strives to contribute significantly to the well-being of millions worldwide. The company is an example of a solution-driven enterprise poised to reshape the healthcare narrative. Its mission revolves around the production of exceptional quality pharmaceuticals, bridging treatment gaps, and redressing unmet medical needs even within the realm of rare diseases. The company's unwavering dedication to maintaining affordability and accessibility underscores its commitment to catalyzing transformative changes in global healthcare.

The company has garnered the trust of millions and traces its origins to the humble town of Panipat in Haryana, India. The journey of Laborate Pharmaceuticals, from a modest retail counter to an international pharmaceutical powerhouse, is a testament to the transformative power of vision, unwavering commitment to quality, and strategic diversification. The seeds of this remarkable odyssey were sown in the family-owned Bhatia Medical Store, a small retail counter where Prithviraj Bhatia, the grandfather of the current generation of leaders, began his foray into the pharmaceutical world. Little did he know that this humble establishment would serve as the cradle of innovation for a future pharmaceutical venture. From these modest beginnings, a legacy was born that would shape the destiny of not just a family, but an entire industry.

A Vision Fueled by Experience

The transformative journey of Laborate Pharmaceuticals commenced over four decades ago, ignited by the enterprising spirit of Prithviraj Bhatia’s sons, Ajay and Sanjay Bhatia. In a time when the pharmaceutical landscape was vastly different from what it is today, these visionary brothers embarked on a mission to turn their dream of manufacturing medicines into reality. It was a time when the pharmaceutical industry was yet to embrace the prominence of generic medicines, and the notion of a textile-focused town like Panipat emerging as a pharmaceutical hub seemed implausible. However, the Bhatia brothers were undeterred by the challenges that lay ahead. Its journey began with a strategic focus on exporting injectables, a segment known for its complexity and stringent quality standards.

Through sheer dedication and relentless perseverance, they managed to establish a foothold in the international market, gradually expanding their presence to 55 countries including WHO GMP, DMP - Ivory Coast, NAFDA - Nigeria, SBDMA -Yemen, MOH - Combodia, MOH - Sri Lanka, MOH - Iraq, NDA- Uganda, PPB - Kenya, MOH - Syria, PMPB - Malawi, MOH - Tajikistan, MOH - Uzbekistan and MOH - Afghanistan within a mere 13 years. This rapid ascent was fueled by an unflinching commitment to quality and innovation, laying the groundwork for Laborate Pharmaceuticals' future endeavors. “Laborate Pharmaceuticals' growth trajectory extends beyond the boundaries of the Indian subcontinent. With a presence in exports spanning 55 countries, Laborate has successfully established its global footprint”, says Parag Bhatia, Director of Laborate Pharmaceuticals.

Unique Distribution Model at National Level

In 1998, sensing the burgeoning potential of the domestic generic market in India, Laborate Pharmaceuticals took a monumental step forward by entering the national arena. An essential aspect of Laborate Pharmaceuticals’ success lies in its innovative distribution model. The introduction of Direct to Stockiest (DTS) system via its main division - ELITE (since 1985), Distribution Model via GPP (since 2012), Personal Care Division - LABOLIA (since 2014) and Retail based division - AQUALAB (since 2021) and filled with love and trust of their customers, now they have launched a new division in April 2023- EXOTIC.

Laborate Pharmaceuticals managed to provide cost-effective medicines without compromising on quality – a rare feat that set them apart in an industry often dominated by larger conglomerates. Proudly emblazoning the label "In-House Production" on nearly 90 percent of its product range, the company showcases its dedication to maintaining stringent quality control measures. This commitment has proven to be a significant advantage, enabling Laborate Pharmaceuticals to meet surges in demand during critical junctures, such as the recent outbreak of conjunctivitis, where it distributed 1 million vials of eye drops and 10 million injections per day across the length and breadth of India. “Laborate has demonstrated its commitment to meet diverse healthcare needs as healthcare is not a privilege, but a basic human right”, adds Sanjay Bhatia, Director of Laborate.

The Transition to Branded Generics

A pivotal juncture in Laborate Pharmaceuticals' trajectory is marked by its strategic shift from generic medicines to branded generics. This transition reflects the company's astute responsiveness to evolving regulations, such as the National Medical Council's directive to prescribe medicines by its generic names rather than brand names. Recognizing the increasing influence wielded by retailers and wholesalers in the prescription process, Laborate Pharmaceuticals proactively focuses on nurturing these relationships, aligning its strategy with the changing dynamics of the industry. This adaptability and forward-looking approach have become emblematic of the company's ethos. Diversification emerges as a key pillar of Laborate Pharmaceuticals' growth strategy. The company has effectively ventured into multiple segments, including analgesics, antibiotics, cardi-vscular, corticosteroids, NSAIDS, Anti-allergic, Anti-asthametic, Psychotropic, Liquid injections, Eye/ear drops, Derma products, and more. The entire product range covers approximately 1000 products. This strategic expansion highlights Laborate's ability to explore new horizons while steadfastly upholding its core commitment to delivering quality healthcare solutions at affordable prices. The Company's upcoming venture into the European Union not only signifies a significant leap forward but also underscores its dedication to adhering to the stringent regulatory standards of this prominent market. This foray exemplifies the company's ambition to further expand its reach and impact on a global scale.

Precision through Technology

The success of Laborate Pharmaceuticals can be attributed with company’s constant dedication to increase its production capacity with improvised technology. Laborate is coming with a new state of art manufacturing plant in 8,50,000 square feet land. This plant is equipped with fully automatic machines with no human touch for OSD & injection with a capacity of 20 million tablets, 10 million capsules & 2 million injections in a day. Company has aim to open European & Australia market with this regulated plant. One of the most striking facets is the company's unwavering investment in quality control. Boasting an impressive array of 37 High- Performance Liquid Chromatography (HPLC) units, Laborate Pharmaceuticals employs cutting-edge technology to ensure the quality and efficacy of its products. Moreover, the state-of-the-art micro lab stands as a testament to the company's unyielding commitment to delivering safe and reliable medicines, with minimal risk of contamination. The strong and enduring relationships that Laborate Pharmaceuticals maintains with its vendors contribute significantly to its success story. "By 2028, we aim to achieve a turnover of 4000 Cr and plan to expand into Animal healthcare", adds Ajay Bhatia, Chairman.

Beyond its products and processes, Laborate Pharmaceuticals' emphasis on people is evident in every facet of its operations. With an employee base numbering between 3,000 to 4,000 individuals, the company recognizes its responsibility towards numerous families. This deep-rooted sense of duty extends to channel partners and customers, as exemplified by initiatives like the Fundose event. Going beyond a mere celebration of achievements, this annual event serves as a platform for motivation and empowerment, fostering a sense of belonging and community.

Future Projections

As Laborate Pharmaceuticals casts its gaze toward the future, the horizon appears luminous with possibilities. In the domestic market, the company aims to fortify its position as a leading player in the generic pharmaceutical segment while concurrently expanding its footprint in the realm of branded generics. On the international stage, the company's growth trajectory is poised to accelerate, with ambitious plans to enter regulated markets and eventually establish a presence in the highly coveted US market.

In a resounding culmination, the saga of Laborate Pharmaceuticals encapsulates the profound essence of a journey marked by vision, unyielding commitment to quality, and the strategic foresight to evolve and adapt. This narrative stands as an inspiring beacon not only for the pharmaceutical industry but for all endeavors, underscoring the transformative power of innovation, the strength of relationships, and the unwavering focus on quality as the cornerstones of enduring success. “With our strong foundation and an unshakable commitment to our core values, we stand poised to chart even more remarkable chapters in the tapestry of our legacy”, concludes Arpit Bhatia, Director.